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Available online xxxxBackground: Approximately 25% of elite controllers (ECs) lose their virological control by mechanisms that are
only partially known. Recently, immunovirological and proteomic factors have been associated to the loss of
spontaneous control. Our aim was to perform a metabolomic approach to identify the underlying mechanistic
pathways and potential biomarkers associated with this loss of control.
Methods: Plasma samples from EC who spontaneously lost virological control (Transient Controllers, TC, n= 8),
at two and one year before the loss of control, were comparedwith a control group of ECwho persistentlymain-
tained virological control during the same follow-up period (Persistent Controllers, PC,n=8). The determination
of metabolites and plasma lipids was performed by GC-qTOF and LC-qTOF using targeted and untargeted ap-
proaches. Metabolite levels were associated with the polyfunctionality of HIV-speciﬁc CD8+T-cell response.
Findings: Our data suggest that, before the loss of control, TCs showed a speciﬁc circulating metabolomic proﬁle
characterized by aerobic glycolytic metabolism, deregulated mitochondrial function, oxidative stress and
increased immunological activation. In addition, CD8+ T-cell polyfunctionality was strongly associated with me-
tabolite levels. Finally, valine was the main differentiating factor between TCs and PCs.
Interpretation: All these metabolomic differences should be considered not only as potential biomarkers but also
as therapeutic targets in HIV infection.
Fund: This work was supported by grants from Fondo de Investigación Sanitaria, Instituto de Salud Carlos III,
Fondos FEDER; Red de Investigación en Sida, Gilead Fellowship program, Spanish Ministry of Education and
Spanish Ministry of Economy and Competitiveness.
© 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
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Elite controllers (ECs) are rare individuals who are able to natu-
rally control viral load (VL) below the detection limit in the absence
of combined antiretroviral therapy (cART) [1]. It has been suggested
that ECs hold the key to how a functional HIV cure can be reached [2].
In-depth characterization of these patients has identiﬁed multiple
immunological mechanisms involved in the controller phenomenon
including host genetic factors, such as HLA-B*57 prevalence [3], a
distinct and effective HIV-1-speciﬁc T-cell response mediated by
high cytokine and chemokine production [4,5] and a remarkably
broad array of HLA class II molecules [6].the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Research in context
Evidence before this study
Elite controllers are those HIV-infected patients who maintain an
undetectable viral load without the use of combined antiretroviral
treatment. This definition makes them the closest model to the
functional HIV cure. However, some studies have elucidated
that this group of patient is not homogeneous. Actually, there is
a subgroup of elite controllers who eventually loses viral control.
The mechanisms that dictate whether an elite controller is going
to lose the virological control are still unknown.
Added value of this study
Previous studies reported that differences in metabolite plasma
levels are relate to changes in the metabolic flux of T-cells due to
its effector functions need significant energetic and biosynthetic
requirements. However, these metabolic alterations have not
been described in relation to HIV spontaneous control, neither
have been associated to immune parameters associated with per-
sistent HIV control. We found for the first time a metabolic
reprogramming associated with persistent HIV spontaneous con-
trol consisting in increased glycolyis in subjects who were going
to transiently control HIV. Importantly this metabolic profiling
was associated with HIV-specific CD8+ T-cell response, one of
the main factors associated to HIV spontaneous control to date.
Implications of all the available evidence
The current study envisages a specific metabolomic signature as-
sociated with the spontaneous loss of virological control in elite
controllers. This metabolic profile was characterized by
immunometabolism deregulation. All these observed metabolic
differences can not only be used as potential biomarkers for a
rapid screening of the loss of spontaneous virological control but
can also be suggested as susceptible targets for the design of im-
munotherapeutic strategies in order to achieve the long-term HIV
remission without treatment.
Fig. 1. Schematic representation of the study design and follow-up timepoints determined
in transient controllers (TCs) and in persistent controllers (PCs).
2 L. Tarancon-Diez et al. / EBioMedicine xxx (2019) xxxSeveral observations have conﬁrmed that ECs are heterogeneous
from a clinical point of view and with regard to both immunological
[7–9] and virological features, including a variable proportion of ECs
who lose HIV control over time [10,11]. That heterogeneity also reﬂects
that no singlemechanism is responsible for controlling viral replication.
In fact, recent ﬁndings have identiﬁed persistent controllers (PCs), com-
pared to subjects who eventually lose viral control, as subjects with low
viral diversity, low HIV-DNA levels, decreased immune activation and
proinﬂammatory cytokine levels, efﬁcient high Gag-speciﬁc T-cell
polyfunctionality and a proteomic proﬁle characterized by lower levels
of inﬂammation, transendothelial migration and coagulation [12–15].
PCs may help to deﬁne the right model of functional cure and may be
a good example for the design of eradication strategies and HIV vaccine
development.
New studies of immune system metabolism (“immunomet-
abolism”) have tried to explore the role of metabolic pathways within
immune cells and how this interplay regulates immune response out-
comes. It is becoming apparent that changes in themetabolomic proﬁle
of cells upon viral infection are important for viral replication and im-
portantly for the seeding of HIV reservoir in CD4+ T-cells [16–18]. The
measurement of speciﬁc metabolic products in plasma has revealed dif-
ferences in the phenotypes of HIV-infected individuals and identiﬁedPlease cite this article as: L. Tarancon-Diez, E. Rodríguez-Gallego, A. Rull, e
elite control of HIV-1 infection, EBioMedicine, https://doi.org/10.1016/j.ebbiomarkers associatedwithHIVnatural evolution [19–21] thatmay par-
ticipate in viral containment together with distinct immune features.
While not much is known in HIV-1 controllers, a distinct tryptophan
catabolic feature may explain the persistence of the functional T-cell re-
sponse [22,23]. However, to date, no longitudinal study determining the
metabolomic proﬁle associated with the loss of spontaneous HIV-1 elite
control has been performed, and there is no evidence of an interplay be-
tween themetabolic signature and immune outcomes in these patients.
Given the importance of immunometabolism in HIV-1 infection and
the lack of metabolomic information in this heterogeneous group of
HIV-infected patients, the performance of metabolomic approaches
could reveal important metabolic differences between persistent and
transient elite controllers, which could lead to new insights into future
designs of effective vaccines and cure strategies using persistent sponta-
neous control as a model. Therefore, the purpose of this study was to
perform targeted and untargeted metabolomic strategies in order to
study the underlyingmechanisms associated with the loss of spontane-
ous virological control in ECs and to identify potential predictive bio-
markers that could explain the inefﬁcient HIV-speciﬁc T-cell response
observed in transient controllers.
2. Methods
2.1. Patients and study design
ECs were deﬁned as subjects with VL determinations below the de-
tection limit (b50 HIV-1-RNA copies/mL) in the absence of cART for at
least 12 months. A total of 16 subjects were included in the study
based on frozen plasma and peripheral blood mononuclear cell
(PBMC) sample availability according to a similar study design that
was previously described [12,13] (Fig. 1). The samples were received,
processed and stored in the Spanish HIV HGM BioBank belonging to
the AIDS Research Network (RIS) [24], and data were registered in the
RIS cohort of HIV Controllers Study Group (ECRIS) (Annex I, Supple-
mentary Material). A detailed description of the cohort's characteristics
has been previously published [11,25]. The 16 subjects were analysed;
eight ECswhoexperienced loss of spontaneous virological HIV-1 control
(at least two consecutive measurements of VL above the detection limit
in 12 months) were called transient controllers “TCs”, and another
group of eight ECs who persistently maintained virological control dur-
ing the same follow-up period were called persistent controllers “PCs”
(see the study design in Fig. 1). Up to four determinationswere assessed
in TCs: at two years and one year before the loss of virological control,
“pre-loss of control period”, (−T2 and –T1 respectively), and two deter-
minations in the “post-loss of control period”, including the closest time
point and one year after the loss of virological control (+T1 and + T2,
respectively). In PCs, up to two determinations were assessed at one-
year intervals (+T1 and +T2).
None of the subjects took drugs with knownmetabolic effects (such
as lipid-lowering agents or antidiabetics agents, among others). As an
example, it has been well described the immunomudulatory andt al., Immunometabolism is a key factor for the persistent spontaneous
iom.2019.03.004
3L. Tarancon-Diez et al. / EBioMedicine xxx (2019) xxxanti-inﬂammatory effects of statins in infectious disease [26].Therefore,
its use may bias immune response and lipidomics results. For this rea-
son, its use was considered within the exclusion criteria. All subjects in-
cluded in the study gave their informed consent, and protocols were
approved by the institutional ethical committees.
Laboratory evaluations were performed at the Laboratory of Joan
XXIII University Hospital in Tarragona, IISPV, Rovira i Virgili University
(Spain) and at the Laboratory of Immunovirology, Institute of Biomedi-
cine of Seville (IBiS), Virgen del Rocío University Hospital in Seville
(Spain).2.2. Laboratory determinations
Absolute counts of CD4+ and CD8+ T-cells were determined in fresh
whole blood by using an Epic XL-MCL ﬂow cytometer (Beckman-Coul-
ter, Brea, California) according to the manufacturers' instructions.
Plasma HIV-1 RNA concentration was measured by quantitative poly-
merase chain reaction (COBAS Ampliprep/COBAS Taqman HIV-1 test,
Roche Molecular Systems, Basel, Switzerland) according to the manu-
facturer's protocol. The detection limit for this assay was 50 HIV-1-
RNA copies/mL. Hepatitis C virus (HCV) RNA was determined using an
available PCR procedure Kit (COBAS Amplicor, Roche Diagnosis, Barce-
lona, Spain) with a detection limit of 10 IU/mL.
Total DNA was extracted from peripheral blood mononuclear cells
(PBMCs) using the MagNa Pure LC DNA isolation kit. HLA-B group al-
leles were genotyped using a reverse sequence-speciﬁc oligonucleotide
bound to a ﬂuorescently coded microsphere system (LABType SSO,
RSSO1B, One Lambda, Canoga Park, CA), following manufacturer's
instructions.2.3. Determination of the Krebs cycle metabolites and energy metabolism
by GC-(EI)qTOF/MS
Metabolite extraction fromplasma sampleswas performed by a pro-
tein precipitationmethod withmethanol/water 8:1 (v/v) containing an
internal standard mixture. Supernatants were collected and evaporated
to dryness under N2 stream and freeze dried before derivatization with
methoxyamine hydrochloride and MSTFA +1% TMCS. Samples were
analysed on a 7200 GC-QTOF Gas chromatograph-quadrupole time of
ﬂight mass spectrometer (GC-qTOF) from Agilent Technologies (Sta.
Clara, CA, USA) using a HP5-MS chromatographic column from J&WSci-
entiﬁc (30 m × 0·25 mm i.d., 0·25 μm ﬁlm) and helium (99·999% pu-
rity) as a carrier gas. Ionization was performed by electronic impact
(EI), with an electron energy of 70 eV, and themass analyzer was oper-
ated in Full Scan mode, recording data in a range between 35 and
700 m/z at a scan rate of 5 spec/s [27,28].
Absolute quantiﬁcation of the Krebs cycle metabolites was per-
formed with an internal standard calibration curve using the corre-
sponding analytical standard for each determined metabolite and a
deuterated internal standard depending on the family of metabolite.
In addition, an untargeted approach was performed by deconvoluting
the acquired raw data by Unknown Analysis software from Agilent
and using FiehnRT library to identify by EI-MS spectra and library reten-
tion time the compounds present in the sample. For these compounds,
their peak areas were used for relative quantiﬁcation between samples.2.4. Liposcale test
We measured triglyceride and cholesterol concentrations, the size
and particle numbers for very-low-density lipoprotein (VLDL), low-
density lipoprotein (LDL) and high-density lipoprotein (HDL) classes,
and the particle numbers of nine subclasses: large, medium and small
VLDLs, LDLs and HDLs of frozen samples using the Liposcale test as de-
scribed elsewhere [29–31].Please cite this article as: L. Tarancon-Diez, E. Rodríguez-Gallego, A. Rull, et
elite control of HIV-1 infection, EBioMedicine, https://doi.org/10.1016/j.eb2.5. Lipidomic analysis by LC-qTOF/MS
Lipid extraction from plasma samples was carried out by a liquid-
liquid extraction using methyl-tert-butyl ether/methanol/water. Then,
the upper organic layer was collected, evaporated to dryness in a
SpeedVac concentrator and reconstituted with methanol:toluene (9:1,
v,v) for analysis by UHPLC-(ESI)qTOF.
Samples were analysed on an Agilent 1290 Inﬁnity UHPLC coupled
to an Agilent 6550 qTOF mass spectrometer. The chromatographic col-
umn used was a Kinetex C18-EVO (2·1 × 100 mm, 2 · 7 μm) from
Phenomenex, and the mobile phase was 2-propanol/methanol/water
(5:4:1) and 2-propanol/water (99:1), both with 5 mM NH4OAc and
0·1% acetic acid. The mass spectrometry analysis was performed both
in positive and negative ionization in separated runs operating in full
scan mode between 300 and 1200m/z at 2 spectra/s. Additionally, tan-
dem mass analysis (MS/MS) was performed at a ﬁxed collision energy
of 20 eV for a data dependence analysis (DDA) using the 10 most
abundant precursor ions with a dynamic exclusion of 30 s for lipid
identiﬁcation.
Data analysis was performed using Mass Proﬁnder software from
Agilent Technologies for raw data signal deconvolution using recursive
feature extraction algorithm for these features previously identiﬁed
with SimLipid software (PREMIER Biosoft), ((http://www.lipidmaps.
org/). The generated features were aligned across all samples to create
a compound matrix to perform statistical analyses.
2.6. Cell stimulation and intracellular cytokine staining
The stimulation assay and intracellular cytokine staining analysis
were evaluated previously in a study with a different objective [12].
Brieﬂy, PBMCs were thawed, washed and in vitro stimulated with 2
μg/mL of overlapped HIV (Gag)-speciﬁc peptide pool (NIH AIDS Re-
search and Referenced Reagent Program (https:// www.aidsreagent.
org/index.cfm) and stained with conjugated monoclonal anti-CD107a-
BV786 (cloneH4A3; BDBiosciences, Franklin Lakes, NJ) at the beginning
of incubation as previously described [4,12].
Stimulated PBMCswerewashed and stainedwith LIVE/DEADﬁxable
Violet Dead Cell Stain (Life Technologies, CA, USA). Then, cells were
surface stained with anti-CD14-PB, anti-CD19-PB, anti-CD56-PB
(Biolegend, San Diego, CA), anti-CD8+-PerCP-Cy5.5, anti-CD45RA-
FITC, anti-CD27-BV605 and anti-CD57-PE-CF595 (BD Biosciences).
Cells were then stained intracellularly for 30 min with 100 μl of PBS
with anti-CD3-APC-H7, anti-IFN-γ-PCy7, anti-TNF-α-Alexa700, anti-
IL-2-APC and anti-Perforin-PE (BD Biosciences) and then washed
twice and ﬁxed in PBS containing 4% paraformaldehyde. Unstimulated
condition and cell stimulation with staphylococcal enterotoxin B (SEB)
condition as a positive control were included in each experiment.
Alive lymphocytes were deﬁned as low forward/side scatter, no violet
dead cell staining and expressed CD3, and/or no CD8+ but not CD19,
CD14, and CD56 (Supplementary Fig. 1). PBMCs were analysed by
using an LSR Fortessa Cell Analyzer (BD Biosciences, Spain). Aminimum
of 1,500,000 total events were recorded for each panel and condition.
2.7. Statistical analysis
All variables were considered non-parametric due to the sample
size. Differences between categorical values were determined by the
Chi-square test. Differences between unpaired groupswere determined
by univariate comparisons through the non-parametric Mann-Whitney
U test. Correlations between variables were assessed using the Spear-
man rank test. p values b0·05 were considered statistically signiﬁcant.
Additionally, the fold change (FC) of each variable was calculated as
‘A/B', where ‘A' was the median value of the TC group pre-loss time
points, and ‘B' was median value of the PC group. Alternatively, ‘A' was
the median value of the post-loss time points in TCs, and ‘B‘was theal., Immunometabolism is a key factor for the persistent spontaneous
iom.2019.03.004
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sented with heat maps and hierarchical clustering analysis (HCA).
In PCs, a PCA analysis andWilcoxon signed-rank testwere applied in
paired samples to assess metabolite changes as an effect of time. As
shown in Supplementary Fig. 2, no changes were observed over time
in PCs. Thus, we simpliﬁed the following analysis to a single variable,
whichwas expressed as themean value of the two consecutive longitu-
dinal determinations in PCs.We then focused the analysis on pre-loss of
control time points fromTCs compared to PCs in order to identify poten-
tial biomarkers for the loss of spontaneous HIV-1 control. To simplify,
for all the comparisons, we conﬁrmed that no differences were ob-
served between –T1 and –T2, and +T1 and +T2 (data not shown),
and the mean values of the –T1 and –T2 time points (pre-loss time
point) and +T1 and +T2 time points (post-loss time point) were
calculated.
Multivariate statistics were also used to improve the reﬁning and
distilling of all the metabolomics data and for pattern recognition pur-
poses. Thus, principal component analysis (PCA) was performed. More-
over, random forest analysis receiver operating characteristic (ROC)
curves were also generated to identify the variables that make the larg-
est contributions to the discrimination between groups.
Polyfunctionalitywas deﬁned as the percentage of lymphocytes pro-
ducing multiple cytokines. Polyfunctionality was quantiﬁed with the
polyfunctionality index algorithm [32] employing the 0.1.2 beta version
of the “FunkyCells Boolean Dataminer” software (www.FunkyCells.
com) provided by Dr. Martin Larson (INSERM U1135, Paris, France).
The statistical software used included the programme ‘R', version
3.4.4 (http://cran.r-project.org) and the SPSS 23.0 package (IBM,
Madrid, Spain). Graphs were generated with Prism, version 5.0
(GraphPad Software, Inc.).3. Results
3.1. Characteristics of the studied subjects
Subjects were recruited based on samples availability based on the
study design shown in Fig. 1. The clinical and demographic characteris-
tics of the subjects at baseline (ﬁrst follow-up time point) were deﬁned.
As shown in Table 1, no differences were observed in age, sex, transmis-
sion route, HCV coinfection, CD4+ and CD8+ T-cell counts and the CD4:
CD8 ratio between TCs and PCs. The TC group presented a shorter time
since diagnosis than the PC group (median [interquartile range] of 3
[2–8] vs 13 [10–17] years; p = 0·005). The VL evolution from TCs
after the loss of control was 539 [295–1120] at +T1 and 2740
[985–22,250] HIV-RNA copies/mL at +T2. No differences were found
in HLA-B57, 27 and 35 frequencies between groups (p N0.05).Table 1
Patients' characteristics.
Transient
controllers
Persistent
controllers
p-Value
TC (n = 8) PC (n = 8)
Age (years) 41 [34–60] 44 [40–46] 0·635
Male sex, n (%) 5 (62.5) 4 (50) 0·614
IDU, n (%) 3 (37.5) 4 (50) 0·198
Time since diagnosis (years) 3 [2–8] 13 [10–17] 0·005
HCV RNA detected, n (%) 3 (37·5) 3 (37·5) 0·999
CD4+ T-cells (cell/μL) 676 [623–963] 724 [609–985] 0·817
CD8+ T-cells (cell/μL) 787 [553–1162] 636 [432–1026] 0·482
CD4:CD8 Ratio 0.86 [0·53–1·55] 1.08 [0·93–1·47] 0·406
Values from TC are taken from –T2 and values from PC are taken from the ﬁrst follow-up
time point. Values are given as percentage for categorical variables or median and inter-
quartile range for continous variables. The Mann-Whitney U and Chi-squared tests were
used. All p values b0·05 were considered signiﬁcant and are highlighted in bold. IDU, In-
travenous drug users.
Please cite this article as: L. Tarancon-Diez, E. Rodríguez-Gallego, A. Rull, e
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A total of 70metaboliteswere identiﬁed and quantiﬁed byGC-QTOF/
MS in plasma samples. When we focused the analysis on pre-loss of
control time from TCs compared to PCs in order to identify the
metabolomic signature associated with the loss of spontaneous HIV-1
control, only the plasma levels of thirteenmetaboliteswere signiﬁcantly
different (Fig. 2A). Fig. 2B shows the data distribution of some of these
13 signiﬁcantly metabolites. In addition, these 13 metabolites showed
good clustering and reliable differentiation between the two studied
groups (Fig. 2C–D).
A Random Forest analysis (out-of-bag (OOB) error = 12·5%) was
then performed in order to select the best parameter for group discrim-
ination. As shown in Fig. 2E, valine, iminodiacetic acid, 2-ketoisocaproic
acid, pyruvic acid, alpha tocopherol, succinic acid and glycolic acid
showed higher classiﬁcation power (mean decreased accuracy (MDA)
N 50). Finally, receiver operating characteristic (ROC) curves demon-
strated that, among the 13 signiﬁcant metabolites, valine was the only
metabolite that could discriminate TCs from PCs with 100% sensitivity
and speciﬁcity (Fig. 2F).
A metabolic pathway analysis revealed that the most signiﬁcant
deregulated metabolites were mainly involved in glycolysis, the Krebs
cycle and amino acidmetabolism. A schematic representation including
the statistically signiﬁcant metabolites between groups and the rest of
metabolites involved in the pathway are shown in Fig. 3.
Finally, regarding changes in TC metabolites as an effect of detect-
able viremia, only monostearin levels were different between TCs at
pre-loss and post-loss time points, being signiﬁcantly lower after the
loss of control (Supplementary Fig. 3).
3.3. Gag-speciﬁc CD8+ T-cells response is associated with metabolite levels
In a previouswork [12], we showed that PCs presented higher levels
of Gag-speciﬁc CD4+ and CD8+ T-cells than TCs before the loss of con-
trol, as determined by the intracellular production of IFN-γ, TNF-α and
IL-2 by T cells. Polyfunctionality, which is understood as simultaneous
multiple production of these cytokines by T cells, was studied only in
subjects categorized as responders and calculated by the index of
polyfunctionality (pINDEX). T-cell response was deﬁned as the fre-
quency of cells (N0·05%) with detectable IFN-γ, TNF-α and/or IL-2 in-
tracellular cytokine production after stimulation. Due to the low
number of Gag-speciﬁc CD4+ T-cell responders among TCs, polyfunct-
ionality was only assessed in responders with CD8+ T-cells.
To associate immunological changes with the most signiﬁcant met-
abolic results, three-function CD8+ T-cell polyfunctionality (calculated
by the pINDEX) from PCs and TCs before the loss of control was strongly
inversely correlated with alpha tocopherol, pyruvic acid, alpha-
ketoglutaric acid, and 2-ketoisocaproic acid plasma levels (r=−0·82,
p = 0·001; r =−0·78, p = 0·003; r =−0·61, p = 0·035; and r =
−0·618, p=0·032, respectively) and directly associatedwith hexanoic
acid (r = 0·69, p = 0·012) (Fig. 4A–E). The same associations with
those metabolites remained signiﬁcant with 4- and 5-function total
CD8+ T-cell polyfunctionality (cytokine combinations plus CD107a
and plus perforin, respectively; data not shown).
3.4. Plasma lipid analysis comparing persistent controllers and transient
controllers and changes in transient controllers due to the loss of control
Using the Liposcale test we found no signiﬁcant differences in tri-
glycerides, cholesterol and lipoproteins comparing PCs and TCs
before the loss of control. Regarding paired samples from TCs, LDL-
cholesterol, the number of medium LDL particles and non-HDL particles
and the ratio of LDL particles/HDL particles were increased after the loss
of control (p = 0·039, p = 0·007, p = 0·039 and p = 0·015
respectively).t al., Immunometabolism is a key factor for the persistent spontaneous
iom.2019.03.004
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before, we also analysed differences in the plasma lipidome from PCs
and TCs before the loss of control. A total of 334 lipids were detected
in plasma, but only 93 were signiﬁcantly different between the two
groups (Supplementary Table 1). We then ordered these signiﬁcant
lipids according to their classiﬁcation power using a Random Forest
analysis (OOB error = 6·25%). The results demonstrated that only 7
lipids performed with an MDA higher than 50 (Fig. 5A). These plasma
lipid levels were signiﬁcantly lower in TCs before the loss of control
than in PCs, but, more importantly, as shown by the PCA analysis
(Fig. 5B), these lipids had great discriminatory potential between the
studied groups.
Regarding changes in TCplasma lipids as an effect of viral loss of con-
trol, 43 lipids were signiﬁcantly different after the loss of control com-
pared with pre-loss time points in TCs; most of them decreased after
the loss of virological control (Supplementary Fig. 4).
3.5. Lipid levels are associated with Gag-speciﬁc CD8+ T-cell response and
metabolite plasma levels
To identify the associations between lipids and Gag-speciﬁc CD8
+ T-cell response, we focused on the most signiﬁcant lipids associ-
ated with the loss of control mentioned before. All of these plasma
lipid levels were higher in PCs than in TCs before the loss of control,
and interestingly, these levels were strongly and directly associated
with the three-function CD8+ T-cell pINDEX (n=11) (p b 0·001 for
all associations) (Fig. 6A–G). The same associations with these lipids
remained signiﬁcant with 4- and 5-function total CD8+ T-cell
polyfunctionality (plus CD107a and plus perforin, respectively)
(Supplementary Fig. 5 A–H).
Correlations between themost relevant lipids andmetabolites asso-
ciated with the loss of control are represented in Supplementary Fig. 6.
Lipid and metabolite levels were strongly associated in PCs and TCs be-
fore the loss of control (n= 15).
4. Discussion
The current study elucidated a metabolomic signature associated
with the spontaneous persistent elite control of HIV-1 infection and
that distinguish the transient controllers from persistent controllers.
There were strong interrelations among metabolites, lipids levels and
an important immune function parameter associated with spontaneous
control of HIV as is HIV-speciﬁc T-cell response. Moreover, the amino
acid valine stood out as the main differentiating factor between the
studied groups.
Among the observedmetabolomic changes, themost signiﬁcant dif-
ferences were related to metabolic pathways as important as glycolysis,
the Krebs cycle, and amino acid catabolism, mostly that of branched
chain amino acids. Previous studies have demonstrated that all these
pathways are targeted during viral infection [16,33], but so far these
metabolic disturbances in energy metabolism have not been described
in HIV-1 elite controllers.
Immunometabolism is now an important ﬁeld in immunology. Mi-
crobial infections results in important changes to the physiology and
metabolism of innate immunity host cells, such as macrophages and
T-cells. In this sense, differences in metabolite plasma levels may reﬂect
changes in cellular metabolic ﬂux and could be also related to the out-
come of the infectious process [34,35].Fig. 2.Metabolomic analysis comparing PCs and TCs before the loss of natural HIV-1 control. Hea
from green (low abundance) to red (high abundance) represents the normalized abundance in
combined tree showing the clusterization of metabolites (C) and Principal Component Analys
groups (D), TCs (blue, n = 8) and PCs (red, n = 8). Random Forest analysis showed met
characteristic (ROC) curves elucidated the amino acid valine as the main differentiator betw
colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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elite control of HIV-1 infection, EBioMedicine, https://doi.org/10.1016/j.ebT-cell activation, T-cell mediated antiviral responses and other T-cell
effector functions require signiﬁcant energetic and biosynthetic re-
quirements from the cell [36,37]. During HIV infection, energy demand
increases dramatically, which is translated as a decrease in circulating
glucose levels (the main cellular energy source) and activation of the
glycolysis pathway [37,38]. This is exactly what we observed in TCs be-
fore the loss of control: a lower glucose concentration and a signiﬁcant
increase in glycolytic intermediates, such as 3P-glycerate, phosphoenol-
pyruvate and pyruvate, compared with PCs. Some studies have pro-
posed that the accumulation of glycolytic intermediates is used in
activated T-cells for biosynthetic processes [39]. Moreover, our previous
results demonstrated that TCs are characterized by high immune activa-
tion and a distinct inﬂammatory proﬁle [12,13], which can be explained
by the observed metabolomic differences. Recent studies have also
highlighted the role of glycolytic enzymes and intermediates in regulat-
ing T-cell cytokineproduction, especially IFN-γ, which reinforces our re-
sults [40,41]. Moreover, regarding HIV-1 infection, glucose metabolism
provides precursors for HIV biosynthesis and intermediate enzymes
thatmay disengage glycolysis and regulateHIV reactivation [42]. Impor-
tantly, a recent study has highlighted the important link between in-
creased glycolysis and HIV-1 reservoir seeding in CD4+ T-cells [17].
This is in accordancewith our data in TCwho also showed higher provi-
ral DNA levels [12].
Furthermore, activated T cells undergo a metabolic reprogramming;
instead of relying onmitochondrial oxidative phosphorylation to gener-
ate the energy needed for cellular process, they enhance aerobic glycol-
ysis, a phenomenon commonly known as the Warburg effect [43]. As a
result, activated lymphocytes increase lactate production even in the
presence of oxygen [44,45]. This is exactly what we observed in TCs at
pre-loss time points.
Other studies have proposed lactic acidemia or hyperlactatemia as
an indicator of mitochondrial oxidative deregulation [46–48]. In this
sense, our results showed a general deregulation of the Krebs cycle me-
tabolites in TCs before the loss of control. Actually, only the increased
Krebs cycle intermediates in TCs before the loss of control compared
to PCs are those that can be supplied by anaplerotic reactions. The
most remarkable example is α-ketoglutarate concentration, which
was increased in TCs. This could be directly related to the signiﬁcant de-
crease in glutamate levels. When energy levels are reduced, glutamate
can be converted into α-ketoglutarate and can enter the Krebs cycle
for energy production, trying to fully compensate for the lack of oxida-
tive Krebs cycle activity. Moreover, another indicator of defective mito-
chondrial functionwas the signiﬁcant decrease in succinate levels in TCs
[49–51], reinforcing the key role of mitochondria in the progression of
HIV infection [52,53].
As mentioned before, our results suggested that valine is the
main differentiating factor between PCs and TCs. Valine is one of a
group of the three essential amino acids with crucial roles in metab-
olism, called branched-chain amino acids (BCAAs: leucine, isoleu-
cine and valine) [54]. Our results demonstrated a signiﬁcant
increase in this type of amino acids and in some of their catabolic in-
termediates, such as α-ketoisocaproic acid, in TCs before the loss of
control compared to PCs. In this sense, some previous studies have
linked high concentrations of BCAAs with deﬁciencies in its catabo-
lism [55]. Thus, since the catabolic products of BCAAs could enter
the Krebs cycle for energy generation, the accumulation of these
products may also be related to activated T-cell reprogramming
into glycolytic metabolism, reducing the oxidative phosphorylation
pathways [43,56,57].tmap representation of the fold change of each statistically signiﬁcantmetabolite, the scale
arbitrary unit (A). Box-plots graph of some of the 13 signiﬁcantlymetabolites Hierarchical
is (PCA) showing that these 13 metabolites allow the differentiation between the studied
abolites by importance of classiﬁcation (E). Logistic regression and receiver operator
een PCs and TCs before the loss of control (F). (For interpretation of the references to
t al., Immunometabolism is a key factor for the persistent spontaneous
iom.2019.03.004
Fig. 3. A schematic representation of the relevant deregulatedmetabolic pathways involved in the loss of virological control.Metabolites observed at lower levels in TCs comparedwith PC
are shown in green (dark green p b 0·05, light green p N 0·05); increased levels of metabolites observed in TCs are shown in red (dark red p b 0·05, light red p N 0·05); and undetected
metabolites are shown in white. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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and, therefore, mitochondrial damage and dysfunction [58]. α-
tocopherol, commonly known as vitamin E, plays an important role
as an antioxidant agent and has been used in HIV-infected patients
as a supplement to reduce oxidative stress [59]. Our results demon-
strated that TCs have higher levels of vitamin E that may mirror a
compensatory mechanism.
The changes inmitochondrial dynamics in TCs presented herein also
explain the differences observed in lipid levels. Mitochondria have an
important role in themaintenance of lipid homeostasis by orchestrating
the synthesis of keymembrane phospholipids [60].Moreover, phospho-
lipids are the main building blocks of cell membranes; thus, changes in
phospholipid composition could affect mitochondrial function,Please cite this article as: L. Tarancon-Diez, E. Rodríguez-Gallego, A. Rull, et
elite control of HIV-1 infection, EBioMedicine, https://doi.org/10.1016/j.ebstructure and biogenesis and rely on the metabolism of phospholipids
themselves [61]. Therefore, it is not surprising that phospholipid alter-
ations have been associated with several diseases, including HIV infec-
tion [61,62]. During infection, innate immune cells suffer from
signiﬁcant remodelling of their lipid compartments, including the
plasma membrane [63]. Moreover, lipid synthesis is critical in effector
T-cell differentiation [64] and secondary responses of memory CD8+
T-cells [65]. Interestingly, in Pernas et al., we observed that the effective
Gag-speciﬁc response from PCs was mediated mainly by the central
memory CD8+ T-cell subset [12]. This may explain the associations be-
tween lipid plasma levels and Gag-speciﬁc response that we have
shown in thiswork. The speciﬁc role of each lipid subclasses on immune
cells is uncertain and may vary according to lipid subtypes, butal., Immunometabolism is a key factor for the persistent spontaneous
iom.2019.03.004
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8 L. Tarancon-Diez et al. / EBioMedicine xxx (2019) xxxnew evidence is emerging in the scenario of HIV infection [66–68].
Modulation of fatty acid synthesis and oxidation pathways could be
used as strategies to prevent inﬂammatory T-cell differentiation.
Themain limitation of our study is the small sample size of our study
population. However, as mentioned in previous our published works
using this cohort [12,13], these types of patients are rare, and it is difﬁ-
cult to perform a long follow-up with stored available samples. For this
reason and to try to overcome this constraint, we have used a highly
sensitive mass spectrometry approach. Moreover, the shorter time for
diagnosis observed in TCs may be considered an inherent characteristic
of this group because of the faster loss of EC status.Fig. 5. Lipidomic analysis comparing TCs before the loss of HIV-1 control and PCs. Random For
Analysis (PCA) showing that lipids with a mean decrease in accuracy higher than 50 allowed
= 8) and persistent controllers, (PCs, red, n = 8). (For interpretation of the references to colou
Please cite this article as: L. Tarancon-Diez, E. Rodríguez-Gallego, A. Rull, e
elite control of HIV-1 infection, EBioMedicine, https://doi.org/10.1016/j.ebIn conclusion, this study envisages a speciﬁcmetabolomic proﬁle as-
sociated with the spontaneous loss of virological control in ECs. This
proﬁlewas characterized by T-cellmetabolic reprogramming to the aer-
obic glycolytic pathway and by a decrease in mitochondrial function
and increased oxidative stress and immunological activation. Metabo-
lite and lipid plasma levels were also strongly correlated with immuno-
logical parameters. Moreover, valine could be considered a potential
biomarker for the prediction of virological progression in elite control-
lers. Therefore, all these observed metabolic differences can not only
be used as biomarkers for rapid screening of future loss of spontaneous
control but can also be suggested as therapeutic targets in HIV-1est analysis showed lipid levels by importance of classiﬁcation (A). Principal Component
a great differentiation between the studied groups (B). Transient controllers (TCs, blue, n
r in this ﬁgure legend, the reader is referred to the web version of this article.)
t al., Immunometabolism is a key factor for the persistent spontaneous
iom.2019.03.004
Fig. 6. PC(25:0/18:0), PC(16:0/18:3(6Z,9Z,12Z)) iso2, PC(O-16:0/15:1(9Z)) and PE(21:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) iso2 plasma levels correlations with Gag-speciﬁc CD8+ T-cell
pINDEX 3-function from PCs and TCs before the loss of control (n= 11). An outlier (*) excluded from the analysis (n= 10). The Spearman ρ correlation coefﬁcient test was used.
9L. Tarancon-Diez et al. / EBioMedicine xxx (2019) xxxinfection. New strategies focused on improving metabolic and inﬂam-
matory conditions in HIV-1 patients are needed in order to enhance
protective immunity. In this sense, the use of statin and aspirin are
being use in clinical trials (NCT02081638), and in addition antioxidant
vitamins, amino acids or other dietary supplements have started to be
widespread in the HIV-infected community [18]. Based on our results,
metformin and thiazolidinediones, widely used to treat type 2 diabetes,
could be potential therapies given that it has been demonstrated that
they improve glucose metabolism [69]. Another therapeutic option
could be the use of antioxidants, such us vitamin E mentioned before
[59]. Moreover, some studies are evaluating the potential beneﬁt of ni-
acin or vitamin B3 in reducing immune activation, another important
point during HIV-1 infection [70]. However, further external validation
studies with larger cohorts are needed to consolidate our results in
order to identify the persistent controller phenotype and to pinpoint
susceptible targets for the design of immunotherapeutic strategies
with the aim of achieving long-term HIV remission in the absence
of ART.
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